Laura E. Niklason - Aug 27, 2024 Form 4 Insider Report for Humacyte, Inc. (HUMA)

Signature
/s/ Laura E. Niklason by Dale A. Sander as Attorney-in-Fact
Stock symbol
HUMA
Transactions as of
Aug 27, 2024
Transactions value $
-$5,724,139
Form type
4
Date filed
8/29/2024, 06:48 PM
Previous filing
Jun 17, 2024
Next filing
Sep 3, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HUMA Common Stock Sale -$1.7M -253K -5.54% $6.71 4.31M Aug 27, 2024 By Ayabudge LLC F1, F2
transaction HUMA Common Stock Sale -$1.79M -277K -6.43% $6.47 4.03M Aug 28, 2024 By Ayabudge LLC F1, F3
transaction HUMA Common Stock Sale -$2.24M -352K -8.74% $6.35 3.68M Aug 29, 2024 By Ayabudge LLC F1, F4
holding HUMA Common Stock 241K Aug 27, 2024 Direct
holding HUMA Common Stock 1.15M Aug 27, 2024 By The Niklason Living Trust
holding HUMA Common Stock 510K Aug 27, 2024 By spouse
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for investors to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. Dr. Niklason is treated as indirectly beneficially owning the shares sold, resulting in the requirement to file this Form 4. However, no shares directly beneficially owned by Dr. Niklason were sold in these transactions.
F2 The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $6.58 to $7.075. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $6.36 to $6.60. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $6.13 to $6.56. The Reporting Person undertakes to provide upon request to the SEC staff, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.